128 related articles for article (PubMed ID: 8749780)
1. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869.
Kute TE; Quadri Y; Muss H; Zbieranski N; Cirrincione C; Berry DA; Barcos M; Thor AP; Liu E; Koerner F
Cytometry; 1995 Dec; 22(4):297-306. PubMed ID: 8749780
[TBL] [Abstract][Full Text] [Related]
2. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
3. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
[TBL] [Abstract][Full Text] [Related]
4. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
Chassevent A; Jourdan ML; Romain S; Descotes F; Colonna M; Martin PM; Bolla M; Spyratos F
Clin Cancer Res; 2001 Apr; 7(4):909-17. PubMed ID: 11309341
[TBL] [Abstract][Full Text] [Related]
5. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
[TBL] [Abstract][Full Text] [Related]
6. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
7. DNA analysis in advanced breast cancer.
Leivonen M; Krogerus L; Nordling S
Cancer Detect Prev; 1994; 18(2):87-96. PubMed ID: 8025900
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
[TBL] [Abstract][Full Text] [Related]
9. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of S-phase fraction in T3N0M0 gastric cancer. Implications for adjuvant chemotherapy.
Cascinu S; Graziano F; Catalano V; Valentini M; Rossi MC; Baldelli AM; Ghiselli R; Saba V; Giordani P; Catalano G
Anticancer Res; 2000; 20(5C):3839-42. PubMed ID: 11268464
[TBL] [Abstract][Full Text] [Related]
11. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
[TBL] [Abstract][Full Text] [Related]
12. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).
Dressler LG; Eudey L; Gray R; Tormey DC; McGuire WL; Gilchrist KW; Clark GM; Osborne CK; Mansour EG; Abeloff MD
J Natl Cancer Inst Monogr; 1992; (11):167-72. PubMed ID: 1627424
[TBL] [Abstract][Full Text] [Related]
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
15. Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study Group.
Baldetorp B; Stål O; Ahrens O; Cornelisse C; Corver W; Falkmer U; Fernö M
Cytometry; 1998 Dec; 33(4):385-93. PubMed ID: 9845432
[TBL] [Abstract][Full Text] [Related]
16. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
18. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
19. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates.
Baldetorp B; Bendahl PO; Fernö M; Alanen K; Delle U; Falkmer U; Hansson-Aggesjö B; Höckenström T; Lindgren A; Mossberg L
Cytometry; 1995 Jun; 22(2):115-27. PubMed ID: 7587742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
